| Bioactivity | Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions[1]. |
| Invitro | Efdamrofusp alfa（0.135 mg/mL；0、6、12 或 24 小时）抑制内皮细胞迁移和管形成[1]。Efdamrofusp alfa (0-1000 μg/mL) 在体外抑制补体激活[1]。 Cell Migration Assay [1] Cell Line: |
| In Vivo | Efdamrofusp alfa（13.5 μg；3 天）在激光诱导的 CNV 小鼠模型中抑制补体系统的激活[1]。Efdamrofusp alfa（1.35 mg；单次玻璃体内注射）在非人灵长类动物激光诱导的 CNV 模型中显示出良好的安全性和抗血管生成功效[1]。 Animal Model: |
| Name | Efdamrofusp alfa |
| CAS | 2375661-82-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Shiqi Yang, et al. Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. Sci Transl Med. 2022 Jun;14(647):eabj2177. |